[{"id":"4d03b67b-68b2-483a-a512-97aaeedafd94","acronym":"","url":"https://clinicaltrials.gov/study/NCT03865212","created_at":"2021-01-18T19:03:32.995Z","updated_at":"2024-07-02T16:35:24.120Z","phase":"Phase 1","brief_title":"Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma","source_id_and_acronym":"NCT03865212","lead_sponsor":"Mayo Clinic","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VSV-IFNbetaTYRP1 • Voyager-V1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 01/20/2027","primary_completion_date":" 01/20/2027","study_txt":" Completion: 01/20/2027","study_completion_date":" 01/20/2027","last_update_posted":"2024-01-09"},{"id":"c62276f8-4079-4871-8f86-8a84bf06401d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04551352","created_at":"2021-01-18T21:45:47.134Z","updated_at":"2024-07-02T16:36:03.062Z","phase":"Phase 1","brief_title":"A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas","source_id_and_acronym":"NCT04551352","lead_sponsor":"Hoffmann-La Roche","biomarkers":" BRAF • TYRP1","pipe":"","alterations":" ","tags":["BRAF • TYRP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gazyva (obinutuzumab) • Actemra IV (tocilizumab) • RG6232"],"overall_status":"Completed","enrollment":" Enrollment 20","initiation":"Initiation: 10/28/2020","start_date":" 10/28/2020","primary_txt":" Primary completion: 07/28/2022","primary_completion_date":" 07/28/2022","study_txt":" Completion: 07/28/2022","study_completion_date":" 07/28/2022","last_update_posted":"2022-10-03"}]